Lisata Enters Into Research License With Catalent To Evaluate Efficacy Of Lisata's iRGD Cyclic Peptide Product Candidate, Certepetide, As Payload Used In SMARTag ADC Dual-payload Tech Platform

Benzinga · 2d ago

BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company has entered into a research license with Catalent, Inc. ("Catalent") to evaluate, in a preclinical setting, the efficacy of Lisata's iRGD cyclic peptide product candidate, certepetide, as a payload used in the context of Catalent's SMARTag® antibody-drug conjugate ("ADC") dual-payload technology platform for the treatment of difficult-to-treat-diseases, including advanced solid tumors.   Under the terms of the agreement, Catalent will assume full responsibility for all research and development expenses and Lisata will provide consulting support. Further, Lisata will receive an upfront payment with the possibility of future considerations contingent upon the results of the preclinical evaluation.